Description

Cimeven (ganciclovir) lyophilisate for solution for infusions 500 mg. №1 vial

Ingredients

Active ingredient: Ganciclovir

Dosage

Dosage: The usual dose is 5 mg/kg infused over 1 hour every 12 hours for 14-21 days.

Indications

Indications: Cimeven is indicated for the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients.

Contraindications

Contraindications: Cimeven is contraindicated in patients with hypersensitivity to ganciclovir or acyclovir.

Directions

Administration: Cimeven is for intravenous infusion only. It should be reconstituted and diluted according to the manufacturer’s instructions.

Scientific Evidence

Cimeven (ganciclovir) has been extensively studied for its efficacy in treating CMV infections. Research has shown that ganciclovir inhibits viral DNA synthesis by selectively targeting viral DNA polymerases, thus preventing viral replication. Clinical trials have demonstrated the effectiveness of Cimeven in reducing the progression of CMV retinitis and improving visual outcomes in patients with AIDS.

Additional Information

It is important to monitor renal function regularly during Cimeven therapy due to the potential for renal toxicity. Patients should stay well hydrated during treatment to reduce the risk of nephrotoxicity. Cimeven may also cause bone marrow suppression, leading to anemia, leukopenia, and thrombocytopenia. Close monitoring of blood counts is essential.

Pharmacological Effects: Ganciclovir, the active ingredient in Cimeven, is a synthetic analogue of 2′-deoxyguanosine that exerts its antiviral effects by interfering with viral DNA synthesis. It is phosphorylated by viral and cellular kinases to form ganciclovir triphosphate, which competitively inhibits viral DNA polymerase and incorporates into viral DNA, leading to chain termination.

Comparative Effectiveness: Compared to other antiviral agents, ganciclovir has shown superior efficacy in the treatment of CMV infections, particularly CMV retinitis. Its high selectivity for viral DNA polymerase contributes to its potency against CMV while minimizing adverse effects on host cell DNA replication.